Recent immunotherapeutic strategies based on mAb targeting of immune checkpoint molecules such as PD-1 and its ligand PD-L1 and CTLA4 have shown a promising therapeutic response that leads to increase the functional activation of immune cells and enhanced host anti-tumor immune response in patients with tumors such as malignant melanoma (8, 25), renal cell cancer (30), lung cancer (30) and CRC (7). Here, CTLA4 is linked to neoplasm.